Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: Role of 5-HT3 receptor antagonist.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 08 10 2019
revised: 11 12 2019
accepted: 26 12 2019
pubmed: 12 1 2020
medline: 15 12 2020
entrez: 12 1 2020
Statut: ppublish

Résumé

Confident relationships between diabetes andliver damagehave previously been established. This study was designed to evaluate hepaticinflammation, apoptosis, and endocannabinoid system alterations in diabetes with or withouttropisetrontreatment. Rats were assigned to five equal groups: control, tropisetron, diabetes, tropisetron+diabetes, and glibenclamide+diabetes (n = 7 in each group). Rats were treated with tropisetron (3 mg/kg) and glibenclamide (1 mg/kg) as a positive control for two weeks after type 1 diabetes induction.Inflammatory cytokines tumor necrosis factor-alpha and interleukin 6 (TNF-α and IL-6) levels, apoptotic cells, and fatty acid amide hydrolase (FAAH) enzyme, at both transcriptional and protein levels increased, while the gene expression of cannabinoid receptor 1 (CB1) and its protein level decreased in the diabetic liver compared to the control. Treatment with tropisetron reversed TNF-α, apoptotic index, and endocannabinoid system components. These effects were equipotent with glibenclamide, indicating that tropisetroncan protect liver tissue against diabetic disturbances. These findings strongly support the idea that diabetes-induced liver abnormality is mediated by inflammatory reactions, apoptosis, and endocannabinoid system, and that these effects can be alleviated by using tropisetron as an antioxidant and anti-inflammatory agent.

Identifiants

pubmed: 31926479
pii: S1567-5769(19)32268-4
doi: 10.1016/j.intimp.2019.106158
pii:
doi:

Substances chimiques

Endocannabinoids 0
Interleukin-6 0
Receptor, Cannabinoid, CB1 0
Serotonin 5-HT3 Receptor Antagonists 0
Tumor Necrosis Factor-alpha 0
Tropisetron 6I819NIK1W
Amidohydrolases EC 3.5.-
fatty-acid amide hydrolase EC 3.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106158

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Mohammad Amini (M)

Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.

Ehsan Saboory (E)

Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

Bagher Pourheydar (B)

Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran; Department of Anatomical Sciences, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Morteza Bagheri (M)

Cellular and Molecular Research Center, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Roya Naderi (R)

Nephrology and Kidney Transplant Research Center, Urmia University of Medical Sciences, Urmia, Iran; Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: r_naderi_s@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH